A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment | MicrobiomeTrials← Back to trialsNCT04233190
A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment
CompletedPHASE3INTERVENTIONAL
Trial Details
Start: 2023-04-19Est. Completion: 2024-10-28
Enrollment target: 472 participants Locations- Eurofarma Laboratorios S.A, São Paulo, São Paulo, Brazil
Other microbiome trials you might be interested in
AsthmaChronic Obstructive Pulmonary Disease (COPD)Lung Cancer
Wildfire smoke (WFS) is the leading climate-related risk in Canada and the main source of harmful air pollution. While s…
Vancouver, CanadaEst. completion Aug 31, 2029
AnosmiaChronic Obstructive Pulmonary DiseaseHyposmiaChronic RhinosinusitisAsthma
Background:
Exposure to smoke increases the risk of many diseases. People can be exposed to dangerous levels of smoke d…
Bethesda, United StatesCompleted Oct 31, 2031